Standard Chem. & Pharm. Co., Ltd. Patent applications |
Patent application number | Title | Published |
20140121284 | Stable Pharmaceutical Composition - Provided is a stable pharmaceutical composition having as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, an absorption modulator, and a diluent, wherein the absorption modulator is glycerin, and the diluent is anhydrous dibasic calcium phosphate (CaHPO | 05-01-2014 |
20110218505 | ANTIEMETIC PATCH - An antiemetic patch is provided. The antiemetic patch includes a backing layer, a release liner, and a matrix layer disposed between the backing layer and the release liner. The matrix layer includes an antiemetic composition, and the antiemetic composition includes an antiemetic agent ranged, a permeation enhancer and an adhesive. | 09-08-2011 |
20090318489 | Aporphine compounds and pharmaceutical use thereof - The present invention discloses novel aporphine derivatives. Also, the present invention discloses that these novel aporphine derivatives can be used for treating oxidative stress induced diseases such as cardiovascular disease, diabetes, aging, Alzheimer's disease, kidney disease, cancer or brain ischemic disease etc. | 12-24-2009 |
20090318488 | Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same - The present invention discloses novel pharmaceutically acceptable salts of aporphine compounds and carboxyl-group containing agents. Also, the present invention discloses methods for preparing the pharmaceutically acceptable salts. These pharmaceutically acceptable salts are suitable for use in treating and/or preventing hyperglycemic disease and/or several oxidative stress related diseases. | 12-24-2009 |
20090264495 | ORAL SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION OF INDAPAMIDE, PRODUCTION AND USE THEREOF - An oral sustained-release pharmaceutical composition of indapamide and a process for producing the foregoing pharmaceutical composition are provided. The pharmaceutical composition comprises indapamide in an amount between 0.2% and 4% (w/w) of the composition, a hydrophilic polymer in an amount between 10 % and 30% (w/w) of the composition, a dry binding agent in an amount between 2% and 20% (w/w) of the composition, and an erosion modifier in an amount between 40% and 80% (w/w) of the composition. The sustained-release pharmaceutical composition of indapamide could be obtained at lower expenditure and produced in a safe and economical manner. | 10-22-2009 |